Nektar Therapeutics (NKTR)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$38.87-0.79%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put NKTR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS loss narrows toward zero: Comparison needs review.
View ThesisRevenue is contracting — down about 27% over the past year.
View GrowthManagement screens strong on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 64% in its worst 12-month stretch.
View RiskNKTR’s case rests on clinical efficacy and safety in alopecia areata, despite weak recent financial performance. The latest quarter beat EPS consensus, but NKTR remained unprofitable. It trades at 24× sales versus 10× for peers, near its own 31× history. The price reflects less growth than our forecast, despite that peer premium. Clinical efficacy and safety concerns around REZPEG threaten the case. Our model puts next-quarter miss probability near 35%. Peer multiples imply a price about 49% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. NKTR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering NKTR (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for NKTR in the last 4 months.
Continue this research
Compare NKTR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NKTR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put NKTR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Demonstrate clinical efficacy and safety in alopecia areata
Downgrade indicates concerns over clinical efficacy and safety.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $38.87
The last 12 months of price, then the range of analyst 12-month targets from today’s $38.87.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Maintain strong financial position with capital raises
Financial position under pressure affects capital allocation strategy.
Threatens: Maintain strong financial position with capital raises
Q2 EPS miss raises concerns about financial position.
Advances: Advance rezpegaldesleukin into Phase 3 clinical trials
Phase III timeline supports advancement of rezpegaldesleukin.
